Biosynex (ALBIO) - Net Assets

Latest as of June 2025: €44.31 Million EUR ≈ $51.80 Million USD

Based on the latest financial reports, Biosynex (ALBIO) has net assets worth €44.31 Million EUR (≈ $51.80 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€149.44 Million ≈ $174.71 Million USD) and total liabilities (€105.13 Million ≈ $122.91 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Biosynex liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€44.31 Million
% of Total Assets	29.65%
Annual Growth Rate	N/A
5-Year Change	21.43%
10-Year Change	280.93%
Growth Volatility	1036.26

Biosynex - Net Assets Trend (2006–2024)

This chart illustrates how Biosynex's net assets have evolved over time, based on quarterly financial data. Also explore ALBIO current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Biosynex (2006–2024)

The table below shows the annual net assets of Biosynex from 2006 to 2024. For live valuation and market cap data, see ALBIO company net worth.

Year	Net Assets	Change
2024-12-31	€80.50 Million ≈ $94.11 Million	-35.25%
2023-12-31	€124.31 Million ≈ $145.34 Million	-25.45%
2022-12-31	€166.76 Million ≈ $194.96 Million	-0.62%
2021-12-31	€167.81 Million ≈ $196.18 Million	+153.14%
2020-12-31	€66.29 Million ≈ $77.50 Million	+118.21%
2019-12-31	€30.38 Million ≈ $35.52 Million	+3.81%
2018-12-31	€29.26 Million ≈ $34.21 Million	+1.23%
2017-12-31	€28.91 Million ≈ $33.80 Million	+18.65%
2016-12-31	€24.36 Million ≈ $28.48 Million	+15.30%
2015-12-31	€21.13 Million ≈ $24.70 Million	+512.55%
2014-12-31	€3.45 Million ≈ $4.03 Million	-12.80%
2013-12-31	€3.96 Million ≈ $4.63 Million	-23.58%
2012-12-31	€5.18 Million ≈ $6.05 Million	+0.27%
2011-12-31	€5.16 Million ≈ $6.04 Million	+4044.19%
2010-12-31	€124.59K ≈ $145.65K	+136.48%
2009-12-31	€-341.55K ≈ $-399.30K	-122.16%
2008-12-31	€-153.74K ≈ $-179.73K	-27.05%
2007-12-31	€-121.00K ≈ $-141.46K	-3933.33%
2006-12-31	€-3.00K ≈ $-3.51K	--

Equity Component Analysis

This analysis shows how different components contribute to Biosynex's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 7437148300.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	€73.80 Million	91.59%
Common Stock	€1.08 Million	1.34%
Other Comprehensive Income	€-19.90 Million	-24.69%
Other Components	€25.60 Million	31.77%
Total Equity	€80.58 Million	100.00%

Biosynex Competitors by Market Cap

The table below lists competitors of Biosynex ranked by their market capitalization.

Company	Market Cap
Kingsmen C.M.T.I. Public Company Limited BK:K	$15.75 Million
Hank Payments Corp V:HANK	$15.76 Million
Laser Photonics Corporation Common Stock NASDAQ:LASE	$15.77 Million
Hanchang KO:005110	$15.81 Million
Currys PLC LSE:CURY	$15.73 Million
Clean Seas Seafood Limited F:C7S	$15.73 Million
Ovanti Ltd AU:OVT	$15.73 Million
NexturnBioscience Co. Ltd KQ:089140	$15.73 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Biosynex's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 124,480,000 to 80,576,000, a change of -43,904,000 (-35.3%).
Net loss of 43,300,000 reduced equity.
Other comprehensive income decreased equity by 62,392,000.
Other factors increased equity by 61,788,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-43.30 Million	-53.74%
Other Comprehensive Income	€-62.39 Million	-77.43%
Other Changes	€61.79 Million	+76.68%
Total Change	€-	-35.27%

Book Value vs Market Value Analysis

This analysis compares Biosynex's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.13x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2008-12-31	€-0.15	€0.78	x
2009-12-31	€-0.32	€0.78	x
2010-12-31	€0.12	€0.78	x
2011-12-31	€4.77	€0.78	x
2012-12-31	€4.38	€0.78	x
2013-12-31	€3.16	€0.78	x
2014-12-31	€2.15	€0.78	x
2015-12-31	€3.42	€0.78	x
2016-12-31	€3.03	€0.78	x
2017-12-31	€3.16	€0.78	x
2018-12-31	€3.20	€0.78	x
2019-12-31	€3.33	€0.78	x
2020-12-31	€6.44	€0.78	x
2021-12-31	€16.15	€0.78	x
2022-12-31	€15.81	€0.78	x
2023-12-31	€9.60	€0.78	x
2024-12-31	€6.18	€0.78	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Biosynex utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -53.74%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -42.79%
• Asset Turnover: 0.52x
• Equity Multiplier: 2.42x
Recent ROE (-53.74%) is below the historical average (-5.43%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2008	0.00%	-33.44%	0.84x	0.00x	€-146.62K
2009	0.00%	-32.60%	1.10x	0.00x	€-190.41K
2010	-23.17%	-2.87%	0.94x	8.57x	€-41.33K
2011	-6.32%	-31.08%	0.17x	1.18x	€-842.81K
2012	-13.95%	-47.13%	0.17x	1.71x	€-1.24 Million
2013	-44.45%	-96.51%	0.25x	1.85x	€-2.15 Million
2014	-44.34%	-35.08%	0.64x	1.97x	€-1.87 Million
2015	-1.72%	-3.58%	0.36x	1.32x	€-2.48 Million
2016	-0.49%	-0.44%	0.69x	1.62x	€-2.56 Million
2017	1.09%	1.03%	0.76x	1.40x	€-2.58 Million
2018	1.86%	1.73%	0.79x	1.35x	€-2.38 Million
2019	3.61%	3.21%	0.72x	1.56x	€-1.94 Million
2020	47.32%	20.38%	1.22x	1.90x	€24.74 Million
2021	61.98%	27.19%	1.42x	1.60x	€87.22 Million
2022	9.64%	7.96%	0.76x	1.60x	€-582.59K
2023	-29.68%	-39.74%	0.38x	1.94x	€-49.39 Million
2024	-53.74%	-42.79%	0.52x	2.42x	€-51.36 Million

Industry Comparison

This section compares Biosynex's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $15,906,822
Average return on equity (ROE) among peers: -136.78%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Biosynex (ALBIO)	€44.31 Million	0.00%	2.37x	$15.74 Million
Affluent Medical SAS (AFME)	$58.87 Million	-9.92%	0.05x	$110.43 Million
Bluelinea SA (ALBLU)	$2.27 Million	-123.09%	2.06x	$9.16 Million
Carmat (ALCAR)	$7.23 Million	-202.60%	2.04x	$6.37 Million
Diagnostic Medical Systems SA (ALDMS)	$28.27 Million	-4.76%	0.77x	$34.50 Million
Eurobio Scientific SA (ALERS)	$12.23 Million	-63.25%	1.61x	$236.10 Million
Ikonisys SA (ALIKO)	$14.25 Million	-22.74%	0.92x	$21.30 Million
Implanet SA (ALIMP)	$4.68 Million	-91.39%	1.52x	$31.91 Million
Mediantechn (ALMDT)	$1.28 Million	-623.58%	11.58x	$200.33 Million
Mauna Kea Technologies SAS (ALMKT)	$14.09 Million	-89.72%	0.60x	$28.43 Million

About Biosynex

PA:ALBIO France Medical Devices

Market Cap

$16.81 Million

€14.38 Million EUR

Market Cap Rank

#25694 Global

#426 in France

Share Price

€0.78

Change (1 day)

-2.50%

52-Week Range

€0.48 - €1.51

All Time High

€25.28